FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895847496> ?p ?o ?g. }

• W2895847496 abstract "Introduction: Treatment using abiraterone acetate plus prednisone, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improves overall survival (OS) and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada.Methods: We describe provincial differences in access to approved mCRPC therapies. Data sources include the pan-Canadian Oncology Drug Review database, provincial cancer care resources, and correspondence with pharmaceutical companies.Results: Both androgen receptor-axis-targeted therapies (ARATs), abiraterone acetate plus prednisone and enzalutamide, are funded by provinces in the pre-and post-chemotherapy setting, however, sequential ARAT use is not funded. “Sandwich” therapy, where one ARAT is used pre-chemotherapy and a second is used upon progression on chemotherapy, is funded in six provinces: Ontario (ON), Alberta, New Brunswick, Prince Edward Island (PEI), Nova Scotia (NS), and Newfoundland and Labrador. Ra-223 is funded in five provinces: ON, Quebec (QC), British Columbia (BC), Saskatchewan, and Manitoba to varying degrees; ON allows Ra-223 either pre- or post-chemo (not both); QC allows Ra-223 post-chemo unless chemo is not tolerated; BC allows Ra-223 if other life-prolonging mCRPC therapies have been received or ineligible. Cabazitaxel is funded in all provinces post-docetaxel, except QC and PEI. Cabazitaxel is not funded as fist-line treatment for mCPRC or in combination with other agents. In ON, BC, QC, and PEI, cabazitaxel is not funded after progression on an ARAT in the post-chemotherapy setting.Conclusions: While all provinces have access to docetaxel and ARATs, sandwiching sequential ARATs with docetaxel is funded only in select provinces. Ra-223 and cabazitaxel access is not ubiquitous across Canada. Such inequalities in access to life-prolonging therapies could lead to disparities in survival and quality of life among patients with mCRPC. Further research should quantify interprovincial variation in outcomes and cost that may result from variable access." @default.
• W2895847496 created "2018-10-26" @default.
• W2895847496 creator A5000900914 @default.
• W2895847496 creator A5005231494 @default.
• W2895847496 creator A5011787893 @default.
• W2895847496 creator A5027101830 @default.
• W2895847496 creator A5028194267 @default.
• W2895847496 creator A5038614516 @default.
• W2895847496 creator A5053749991 @default.
• W2895847496 creator A5055673305 @default.
• W2895847496 creator A5060092380 @default.
• W2895847496 creator A5081688624 @default.
• W2895847496 creator A5085419329 @default.
• W2895847496 creator A5086687064 @default.
• W2895847496 creator A5091452615 @default.
• W2895847496 date "2018-07-16" @default.
• W2895847496 modified "2023-10-17" @default.
• W2895847496 title "Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces" @default.
• W2895847496 cites W1981319409 @default.
• W2895847496 cites W2028387248 @default.
• W2895847496 cites W2055346449 @default.
• W2895847496 cites W2055847340 @default.
• W2895847496 cites W2080439368 @default.
• W2895847496 cites W2109333569 @default.
• W2895847496 cites W2110534364 @default.
• W2895847496 cites W2118721274 @default.
• W2895847496 cites W2120292596 @default.
• W2895847496 cites W2123526148 @default.
• W2895847496 cites W2135492571 @default.
• W2895847496 cites W2138469052 @default.
• W2895847496 cites W2141454098 @default.
• W2895847496 cites W2148643283 @default.
• W2895847496 cites W2489425084 @default.
• W2895847496 doi "https://doi.org/10.5489/cuaj.5378" @default.
• W2895847496 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6192749" @default.
• W2895847496 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29688882" @default.
• W2895847496 hasPublicationYear "2018" @default.
• W2895847496 type Work @default.
• W2895847496 sameAs 2895847496 @default.
• W2895847496 citedByCount "5" @default.
• W2895847496 countsByYear W28958474962019 @default.
• W2895847496 countsByYear W28958474962021 @default.
• W2895847496 countsByYear W28958474962022 @default.
• W2895847496 countsByYear W28958474962023 @default.
• W2895847496 crossrefType "journal-article" @default.
• W2895847496 hasAuthorship W2895847496A5000900914 @default.
• W2895847496 hasAuthorship W2895847496A5005231494 @default.
• W2895847496 hasAuthorship W2895847496A5011787893 @default.
• W2895847496 hasAuthorship W2895847496A5027101830 @default.
• W2895847496 hasAuthorship W2895847496A5028194267 @default.
• W2895847496 hasAuthorship W2895847496A5038614516 @default.
• W2895847496 hasAuthorship W2895847496A5053749991 @default.
• W2895847496 hasAuthorship W2895847496A5055673305 @default.
• W2895847496 hasAuthorship W2895847496A5060092380 @default.
• W2895847496 hasAuthorship W2895847496A5081688624 @default.
• W2895847496 hasAuthorship W2895847496A5085419329 @default.
• W2895847496 hasAuthorship W2895847496A5086687064 @default.
• W2895847496 hasAuthorship W2895847496A5091452615 @default.
• W2895847496 hasBestOaLocation W28958474961 @default.
• W2895847496 hasConcept C121608353 @default.
• W2895847496 hasConcept C126322002 @default.
• W2895847496 hasConcept C143998085 @default.
• W2895847496 hasConcept C2775832370 @default.
• W2895847496 hasConcept C2776551883 @default.
• W2895847496 hasConcept C2776694085 @default.
• W2895847496 hasConcept C2777899217 @default.
• W2895847496 hasConcept C2778720950 @default.
• W2895847496 hasConcept C2778971682 @default.
• W2895847496 hasConcept C2780192828 @default.
• W2895847496 hasConcept C2781190966 @default.
• W2895847496 hasConcept C512399662 @default.
• W2895847496 hasConcept C61367390 @default.
• W2895847496 hasConcept C71924100 @default.
• W2895847496 hasConceptScore W2895847496C121608353 @default.
• W2895847496 hasConceptScore W2895847496C126322002 @default.
• W2895847496 hasConceptScore W2895847496C143998085 @default.
• W2895847496 hasConceptScore W2895847496C2775832370 @default.
• W2895847496 hasConceptScore W2895847496C2776551883 @default.
• W2895847496 hasConceptScore W2895847496C2776694085 @default.
• W2895847496 hasConceptScore W2895847496C2777899217 @default.
• W2895847496 hasConceptScore W2895847496C2778720950 @default.
• W2895847496 hasConceptScore W2895847496C2778971682 @default.
• W2895847496 hasConceptScore W2895847496C2780192828 @default.
• W2895847496 hasConceptScore W2895847496C2781190966 @default.
• W2895847496 hasConceptScore W2895847496C512399662 @default.
• W2895847496 hasConceptScore W2895847496C61367390 @default.
• W2895847496 hasConceptScore W2895847496C71924100 @default.
• W2895847496 hasIssue "10" @default.
• W2895847496 hasLocation W28958474961 @default.
• W2895847496 hasLocation W28958474962 @default.
• W2895847496 hasLocation W28958474963 @default.
• W2895847496 hasLocation W28958474964 @default.
• W2895847496 hasLocation W28958474965 @default.
• W2895847496 hasOpenAccess W2895847496 @default.
• W2895847496 hasPrimaryLocation W28958474961 @default.
• W2895847496 hasRelatedWork W122177069 @default.
• W2895847496 hasRelatedWork W2135620818 @default.
• W2895847496 hasRelatedWork W2158933186 @default.
• W2895847496 hasRelatedWork W2274307715 @default.
• W2895847496 hasRelatedWork W2568045406 @default.

• next